Cat-PAD Exposure Chamber Study

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2010
Cat allergy is an increasingly prevalent condition, affecting 10-15% of patients with allergic rhinoconjunctivitis and/or asthma. Cat-PAD is a novel, synthetic, allergen-derived peptide desensitising vaccine, currently being developed for the treatment of cat allergy. This study will look at the efficacy, safety and tolerability of two doses of Cat-PAD in cat allergic subjects following challenge to cat allergen in an EEC.
Epistemonikos ID: db74b83eaacbbf2e5e109ca947f3047c5d20b477
First added on: May 05, 2024